Incyte Reports 2018 Fourth Quarter and Year-End Financial Results, Provides 2019 Financial Guidance and Provides Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Incyte (INCY) PT Raised to $89 at RBC Capital
February 15, 2019 7:16 AM ESTRBC Capital analyst Brian Abrahams raised the price target on Incyte (NASDAQ: INCY) to $89.00 (from $81.00) while maintaining a Outperform rating.
The analyst commented, "Coming off of a solid quarter for sales and guidance, we see the potential for some additional appreciation in INCYwith... More
Incyte (INCY) PT Raised to $100 at Raymond James
February 15, 2019 7:10 AM ESTRaymond James analyst Reni Benjamin raised the price target on Incyte (NASDAQ: INCY) to $100.00 (from $85.00) while maintaining a Strong Buy rating following results and guidance.
Benjamin said key takeaways include: 1) The Jakafi franchise remains solid with 2018 sales at $1.39 billion; 2) 2019 guidance is for Jakafi to... More
Incyte (INCY) Misses Q4 EPS by 7c
February 14, 2019 7:04 AM ESTIncyte (NASDAQ: INCY) reported Q4 EPS of $0.40, $0.07 worse than the analyst estimate of $0.47. Revenue for the quarter came in at $468 million versus the consensus estimate of $485.8 million.
2019 Financial... More
